College of Chemistry, Fuzhou University, Fuzhou 350116, China.
Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, China.
Bioorg Med Chem. 2019 Apr 1;27(7):1362-1369. doi: 10.1016/j.bmc.2019.02.041. Epub 2019 Feb 20.
A series of quinizarin derivatives containing quaternary ammonium salts and/or thiourea groups were synthesized and their anticancer activities against leukemia cell lines have been tested. Results showed that most of quinizarin derivatives could inhibit the proliferation of leukemia cells. Among these derivatives, compound 3 showed good inhibition activity against various leukemia cells with IC values ranging from 0.90 ± 2.55 μM to 10.90 ± 3.66 μM. At the same time, compound 3 also inhibited the growth of human embryonic kidney-293 cell (HEK-293). Molt-4 and Jurkat cells, acute T lymphoblastic leukemia (T-ALL) cell lines, were selected to reveal potential anticancer mechanism of compound 3. Compound 3 inhibited the proliferation of Molt-4 and Jurkat cells in a dose- and time-dependent manner and led to a marked G0/G1 phase arrest. Analysis of Annexin V-APC and intracellular reactive oxygen species (ROS) level by flow cytometry showed that compound 3 induced significant apoptosis in Molt-4 and Jurkat cells. Western blotting assay showed that compound 3 activated the caspase-dependent apoptosis pathway and induced the degradation of Bcl-2 and c-myc protein.
一系列含有季铵盐和/或硫脲基团的喹吖啶酮衍生物被合成出来,并对其抗白血病细胞系的抗癌活性进行了测试。结果表明,大多数喹吖啶酮衍生物能够抑制白血病细胞的增殖。在这些衍生物中,化合物 3 对多种白血病细胞表现出良好的抑制活性,IC 值范围为 0.90±2.55μM 至 10.90±3.66μM。同时,化合物 3 还抑制了人胚肾-293 细胞(HEK-293)的生长。选择 Molt-4 和 Jurkat 细胞,即急性 T 淋巴细胞白血病(T-ALL)细胞系,以揭示化合物 3 的潜在抗癌机制。化合物 3 以剂量和时间依赖的方式抑制 Molt-4 和 Jurkat 细胞的增殖,并导致明显的 G0/G1 期阻滞。通过流式细胞术分析 Annexin V-APC 和细胞内活性氧(ROS)水平表明,化合物 3 诱导 Molt-4 和 Jurkat 细胞发生显著的细胞凋亡。Western blot 分析表明,化合物 3 激活了 caspase 依赖性凋亡途径,并诱导了 Bcl-2 和 c-myc 蛋白的降解。